About us

Our strategy

Incanthera has an experienced and diverse team, operating a lean business model by outsourcing all development work ensuring a low internal fixed cost model.

Incanthera

A rich pipeline of future drug candidates provides the opportunities to develop in line with the business strategy.

 

Incanthera

Identify (in active negotiations) potential new assets for in-licensing and a pro-active ‘buy & build’ consolidation strategy will bring in other oncology assets when the opportunities arise.

 

Incanthera

The addition of clinical stage oncology assets will provide a step change in the Company’s portfolio of drugs.